ea0057012 | Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review of the literature | BES2018
de Filette Jeroen MK
, Joeri Pen
, Brigitte Velkeniers
, Kharagjitsingh Aan V
Introduction: Immune checkpoint inhibitors have revolutionized the treatment of advanced malignancies. These monoclonal antibodies target cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death 1 (PD-1) or its ligand (PD-L1). Endocrine side effects are common, and while hypophysitis and thyroid disorders are predominant, checkpoint-blockade associated diabetes mellitus deserves further notice.Methods: We present the case of a 61-year old male wi...